Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 9046 AL 9060

Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review

Ibrahim R, Kambal A, Abdelmajeed MA.

Cureus. 2025 Sep 16;17(9):e92441. doi: 10.7759/cureus.92441. eCollection 2025 Sep.

Unlocking ferulic acid for neurological diseases and tailoring of nanoformulations to advance its brain delivery

de Andrade PRA, Motta RC, Fonseca-Santos B.

Int J Pharm. 2025 Nov 10;684:126173. doi: 10.1016/j.ijpharm.2025.126173. Epub 2025 Sep 16.

Nonmotor fluctuations in Parkinson's disease: impact on caregiving and quality of life

Ledda C, Imbalzano G, Scaglia E, Artusi CA, Nicoletti A, Erro R, Rinaldi D, Gallo S, Montanaro E, Zibetti M, Rizzone MG, Balestrino R, Agosta F, Galli S, Sorrentino C, Indaco D, Donzuso G, Terravecchia C, Filippi M, Lopiano L, Romagnolo A.

J Neurol. 2025 Sep 22;272(9):639. doi: 10.1007/s00415-025-13390-9.

Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme (PBS) Data

Logan PA, Micalos PS, Fealy S, Bramble M, Wong A.

Aust J Rural Health. 2025 Oct;33(5):e70094. doi: 10.1111/ajr.70094.

AZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open-Label Extension on Safety, Biomarkers, and Disease Progression

Corvol JC, Obadia MA, Moreau C, Mariani LL, Brandel JP, Devos D, Sambin S, Carrière N, Höglinger G, Lebouteux M, Mangone G, Callizot N, Blondel A, Defert O, Estrella C, Karapet A, Verwaerde P, Defebvre L.

Mov Disord. 2025 Dec;40(12):2700-2709. doi: 10.1002/mds.70049. Epub 2025 Sep 27.

Lymphomatosis cerebri presenting with rapidly progressive parkinsonism and Holmes tremor: a case report

Iguchi T, Furuya T, Koinuma T, Nakajima A, Fuse A, Eguchi H, Sugiyama Y, Shimo Y.

BMC Neurol. 2025 Sep 29;25(1):392. doi: 10.1186/s12883-025-04426-8.

Burst-type deep brain stimulation of the subthalamic nucleus in Parkinson's disease: A case series on tolerability and efficacy

Jaffee S, Kite T, Kusyk D, Whiting D, Tomycz N.

Surg Neurol Int. 2025 Aug 1;16:318. doi: 10.25259/SNI_266_2025. eCollection 2025.

Human leukocyte antigen in Parkinson's disease: A systematic review and meta-analysis of risk and clinical attributes

Salari M, Rezaei K, Eini P, Alikhani A, Etemadifar M.

Neurol Sci. 2025 Dec;46(12):6321-6332. doi: 10.1007/s10072-025-08525-9. Epub 2025 Oct 1.

Modified Mediterranean diet effects on Parkinson's disease (MED-PARK): a single-centre randomised controlled trial protocol

Pirovano E, Marino F, Rossi E, Gennari A, Rasini E, Uslenghi M, Figueira I, Iacoviello L, Ferrari M, Cosentino M.

BMJ Open. 2025 Oct 5;15(10):e101946. doi: 10.1136/bmjopen-2025-101946.

Efficacy of gut microbiota-targeted therapies in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials

Gu X, Tang J, Chen C.

Front Cell Infect Microbiol. 2025 Sep 25;15:1627406. doi: 10.3389/fcimb.2025.1627406. eCollection 2025.

A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs

Subramanian I, Ricciardi L, Schrag A, Appel-Cresswell S, Kola S, Domingos JM, Pickut BA, Dahodwala N, Bocoum A, Falup-Pecurariu C, Bronner G, Pontone GM, Mischley LK, Garretto NS, Modugno N, Dolhun R, Wijeratne T, Tull V, McDaniels B, Chaudhuri KR; International Parkinson; Movement Disorder Society Task Force on Wellness.

Mov Disord Clin Pract. 2026 Mar;13(3):631-646. doi: 10.1002/mdc3.70381. Epub 2025 Oct 14.

Phase 1/2a clinical trial of hESC-derived dopamine progenitors in Parkinson's disease

Chang JW, Na HK, Chang KW, Park CW, Kim DH, Park S, Park CY, Eom JH, Nam ST, Jo KS, Jo MY, Choi SK, Hur HJ, Kim S, Kim M, Kim DS, Hwang DY, Kim MS, Jung I, Kim J, Cho MS, Lee PH, Kim DW.

Cell. 2025 Dec 11;188(25):7036-7048.e11. doi: 10.1016/j.cell.2025.09.010. Epub 2025 Oct 13.

Pharmacological and non-pharmacological treatments for impulsive-compulsive behaviors in Parkinson's disease

Mantovani E, Martini A, Purgato M, Tamburin S.

Cochrane Database Syst Rev. 2025 Oct 15;10(10):CD015046. doi: 10.1002/14651858.CD015046.pub2.

Intracranial Neural Biomarkers of Psychiatric Symptoms and Their Utility for Guiding Neuromodulation Therapy: A Systematic Review

Kabotyanski KE, Provenza NR, Sheth SA.

Biol Psychiatry. 2026 May 15;99(10):909-922. doi: 10.1016/j.biopsych.2025.10.005. Epub 2025 Oct 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias